ロード中...
BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies
BRAF inhibitors vemurafenib and dabrafenib achieved improved overall survival over chemotherapy and have been approved for the treatment of BRAF-mutated metastatic melanoma. More recently, the combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib has shown improved progression-free...
保存先:
| 出版年: | Onco Targets Ther |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4303458/ https://ncbi.nlm.nih.gov/pubmed/25653539 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S39096 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|